JP5944831B2 - 抗ｆｌｔ３抗体及びその使用方法 - Google Patents

抗ｆｌｔ３抗体及びその使用方法 Download PDF

Info

Publication number
JP5944831B2
JP5944831B2 JP2012545347A JP2012545347A JP5944831B2 JP 5944831 B2 JP5944831 B2 JP 5944831B2 JP 2012545347 A JP2012545347 A JP 2012545347A JP 2012545347 A JP2012545347 A JP 2012545347A JP 5944831 B2 JP5944831 B2 JP 5944831B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
acid sequence
antibodies
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012545347A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515472A5 (enExample
JP2013515472A (ja
Inventor
ルートガー グロセ−ホペスト
ルートガー グロセ−ホペスト
ハンス−イェルク ビューリング
ハンス−イェルク ビューリング
マルティン ホフマン
マルティン ホフマン
シュテフェン アウルヴュルム
シュテフェン アウルヴュルム
グルントラム ユング
グルントラム ユング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synimmune GmbH
Original Assignee
Synimmune GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synimmune GmbH filed Critical Synimmune GmbH
Publication of JP2013515472A publication Critical patent/JP2013515472A/ja
Publication of JP2013515472A5 publication Critical patent/JP2013515472A5/ja
Application granted granted Critical
Publication of JP5944831B2 publication Critical patent/JP5944831B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012545347A 2009-12-23 2010-12-23 抗ｆｌｔ３抗体及びその使用方法 Active JP5944831B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28952909P 2009-12-23 2009-12-23
US61/289,529 2009-12-23
PCT/EP2010/070659 WO2011076922A1 (en) 2009-12-23 2010-12-23 Anti-flt3 antibodies and methods of using the same

Publications (3)

Publication Number Publication Date
JP2013515472A JP2013515472A (ja) 2013-05-09
JP2013515472A5 JP2013515472A5 (enExample) 2014-02-06
JP5944831B2 true JP5944831B2 (ja) 2016-07-05

Family

ID=43719470

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012545347A Active JP5944831B2 (ja) 2009-12-23 2010-12-23 抗ｆｌｔ３抗体及びその使用方法

Country Status (13)

Country Link
US (1) US9023996B2 (enExample)
EP (1) EP2516468B1 (enExample)
JP (1) JP5944831B2 (enExample)
CN (1) CN102770453B (enExample)
BR (1) BR112012015740B1 (enExample)
CA (1) CA2785178C (enExample)
DK (1) DK2516468T3 (enExample)
EA (1) EA027502B1 (enExample)
ES (1) ES2573642T3 (enExample)
HR (1) HRP20160422T1 (enExample)
HU (1) HUE028629T2 (enExample)
SI (1) SI2516468T1 (enExample)
WO (1) WO2011076922A1 (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2794658T3 (en) * 2011-12-19 2017-06-19 Synimmune Gmbh BISPECIFIC ANTIBODY MOLECULE
WO2013106485A2 (en) * 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
KR20160029027A (ko) * 2013-07-04 2016-03-14 프라운호퍼-게젤샤프트 추르 푀르데룽 데어 안제반텐 포르슝 에 파우 급성 골수성 백혈병 세포를 표적으로 하고 치료하는 새로운 융합 단백질
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
CN104288765A (zh) * 2014-07-03 2015-01-21 成都中联生科基因科技有限公司 一种利用具有中和FLT3生物学活性的McAb应用于肿瘤的靶向治疗的新方法
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
RS60998B1 (sr) * 2014-11-21 2020-11-30 Bristol Myers Squibb Co Antitela koja sadrže modifikovane regione teškog lanca
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3268038B1 (en) * 2015-03-09 2021-05-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to flt3 proteins
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
EP3352784A4 (en) * 2015-09-23 2019-06-26 Cytoimmune Therapeutics, LLC FLT3-FACED CAR CELLS FOR IMMUNOTHERAPY
CN108603200B (zh) 2015-11-23 2022-08-19 诺华股份有限公司 优化的慢病毒转移载体及其用途
EP3397756B1 (en) 2015-12-30 2023-03-08 Novartis AG Immune effector cell therapies with enhanced efficacy
WO2017134158A1 (en) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Psma and cd3 bispecific t cell engaging antibody constructs
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
UA128326C2 (uk) * 2016-04-01 2024-06-12 Амджен Інк. Химерний рецептор до flt3 та спосіб його застосування
CA3019581A1 (en) * 2016-04-04 2017-10-12 Hemogenyx Llc Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
US11104738B2 (en) 2016-04-04 2021-08-31 Hemogenyx Pharmaceuticals Llc Monoclonal antibodies to human FLT3/FLK2 receptor protein
KR20190038537A (ko) 2016-06-17 2019-04-08 마젠타 테라퓨틱스 인코포레이티드 Cd117+ 세포의 고갈을 위한 조성물 및 방법
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
CA3045902A1 (en) 2016-12-21 2018-06-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for flt3 and uses thereof
KR102725761B1 (ko) 2017-01-20 2024-11-04 하이델베르크 파마 리서치 게엠베하 Cd137+ 세포의 고갈을 위한 조성물 및 방법
ES2912408T3 (es) 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
JP7116736B2 (ja) * 2017-03-02 2022-08-10 ノバルティス アーゲー 操作されたヘテロ二量体タンパク質
PE20241587A1 (es) * 2017-06-02 2024-08-01 Pfizer Receptores de antigenos quimericos que se dirigen a flt3
TWI790120B (zh) 2017-06-02 2023-01-11 美商輝瑞大藥廠 對flt3具特異性之抗體及其用途
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2019028027A1 (en) * 2017-07-31 2019-02-07 Dragonfly Therapeutics, Inc. PROTEINS BINDING TO NKG2D, CD16 AND FLT3
CA3071303A1 (en) * 2017-08-01 2019-02-07 Julius-Maximilians-Universitat Wurzburg Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
AU2018355427A1 (en) 2017-10-25 2020-04-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
CN119350481A (zh) * 2018-01-26 2025-01-24 建新公司 具有与FcRn增强的结合及延长的半衰期的Fc变体
CA3091424A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
JP7551499B2 (ja) * 2018-03-21 2024-09-17 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｆｃバリアント組成物およびその使用方法
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
SG11202101298XA (en) 2018-08-08 2021-03-30 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and a tumor-associated antigen
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
WO2020053300A1 (en) 2018-09-11 2020-03-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved anti-flt3 antigen binding proteins
EP3623383A1 (en) 2018-09-11 2020-03-18 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved bispecific flt3xcd3 antigen binding proteins
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
SG11202104352XA (en) 2018-12-18 2021-05-28 Boehringer Ingelheim Io Canada Inc Flt3 agonist antibodies and uses thereof
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
BR112021015783A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
CN113329792B (zh) 2019-02-15 2024-06-28 诺华股份有限公司 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
EP3962527A4 (en) 2019-04-30 2023-11-01 Senti Biosciences, Inc. CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
AU2020406350A1 (en) 2019-12-20 2022-08-11 Novartis Ag Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
BR112022016550A2 (pt) * 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
JP7525109B2 (ja) * 2020-03-18 2024-07-30 学校法人金沢医科大学 Ｃｄ１３５＋細胞を含む医薬組成物
CN115715297A (zh) * 2020-04-14 2023-02-24 法国施维雅药厂 抗flt3抗体和组合物
CA3177024A1 (en) 2020-05-06 2021-11-11 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and clec12a
EP4165169A1 (en) 2020-06-11 2023-04-19 Novartis AG Zbtb32 inhibitors and uses thereof
CA3182346A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
AU2021378316A1 (en) 2020-11-13 2023-06-01 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AU2022267891A1 (en) 2021-04-27 2023-11-09 Novartis Ag Viral vector production system
AU2022330106A1 (en) * 2021-08-16 2024-03-21 Hemogenyx Pharmaceuticals Llc Anti-flt3 antibodies, cars, car t cells and methods of use
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
WO2024206669A2 (en) * 2023-03-29 2024-10-03 Virtuoso Binco, Inc. Antibodies for targeting cd47 and b7h3 and methods of use thereof
CN120981456A (zh) 2023-05-24 2025-11-18 金橘生物科技公司 杂环化合物及其用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US572374A (en) 1896-12-01 Rod-cutting apparatus
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5681566A (en) 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1994029351A2 (en) * 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
DE19608769C1 (de) 1996-03-07 1997-04-10 Univ Eberhard Karls Antikörper BV10A4H2
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE19727814C1 (de) 1997-06-30 1998-10-01 Univ Eberhard Karls Anitkörper 4G8B4B12
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6403312B1 (en) 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
US20020048772A1 (en) 2000-02-10 2002-04-25 Dahiyat Bassil I. Protein design automation for protein libraries
US7315786B2 (en) 1998-10-16 2008-01-01 Xencor Protein design automation for protein libraries
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE19958134C2 (de) 1999-12-02 2003-05-15 Koenig & Bauer Ag Saugwalze
WO2002005146A2 (en) 2000-07-10 2002-01-17 Xencor, Inc. Method for disigning protein libraries with altered immunogenicity
AU2001291175A1 (en) 2000-09-21 2002-04-02 Md Online Inc. Medical image processing systems
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
WO2002096910A1 (en) 2001-05-31 2002-12-05 Medarex, Inc. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
WO2003014325A2 (en) 2001-08-10 2003-02-20 Xencor Protein design automation for protein libraries
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
KR20040008359A (ko) 2002-07-18 2004-01-31 삼성전자주식회사 계층적 움직임 벡터 탐색을 이용한 움직임 추정 방법 및장치 및 그를 적용한 동영상 부호화 시스템
CA2832136C (en) * 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
WO2004063963A2 (en) 2003-01-08 2004-07-29 Xencor, Inc. Novel proteins with altered immunogenicity
CA2530065C (en) 2003-06-26 2011-12-20 Rj Mears, Llc Semiconductor device including mosfet having band-engineered superlattice
US20070148170A1 (en) * 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
US20060148009A1 (en) 2004-10-12 2006-07-06 Xencor, Inc. Prediction and assessment of immunogenicity
JP2008537941A (ja) * 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
US20100080794A1 (en) * 2006-04-14 2010-04-01 Takashi Tsuji Mutant polypeptide having effector function
WO2008137382A1 (en) * 2007-04-30 2008-11-13 Centocor, Inc. Anti-tissue factor antibodies and compositions with enhanced effector function
PE20120259A1 (es) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
US9679104B2 (en) 2013-01-17 2017-06-13 Edico Genome, Corp. Bioinformatics systems, apparatuses, and methods executed on an integrated circuit processing platform
US9703321B2 (en) 2013-07-09 2017-07-11 I-Blades, Inc. Snap on wearable module
KR102185854B1 (ko) 2017-09-09 2020-12-02 애플 인크. 생체측정 인증의 구현

Also Published As

Publication number Publication date
HRP20160422T1 (hr) 2016-05-20
CA2785178A1 (en) 2011-06-30
JP2013515472A (ja) 2013-05-09
ES2573642T3 (es) 2016-06-09
SI2516468T1 (sl) 2016-06-30
BR112012015740B1 (pt) 2020-09-29
BR112012015740A2 (pt) 2017-04-25
US20120328612A1 (en) 2012-12-27
EP2516468B1 (en) 2016-03-02
EA201290370A1 (ru) 2013-04-30
HUE028629T2 (en) 2016-12-28
WO2011076922A1 (en) 2011-06-30
EA027502B1 (ru) 2017-08-31
EP2516468A1 (en) 2012-10-31
CN102770453A (zh) 2012-11-07
CA2785178C (en) 2019-09-03
CN102770453B (zh) 2014-10-08
US9023996B2 (en) 2015-05-05
HK1172910A1 (zh) 2013-05-03
DK2516468T3 (en) 2016-05-23

Similar Documents

Publication Publication Date Title
JP5944831B2 (ja) 抗ｆｌｔ３抗体及びその使用方法
JP5562031B2 (ja) Ｈｍ１．２４を標的とする最適化抗体
JP5357778B2 (ja) 最適化ｃｄ４０抗体および前記を使用する方法
ES2457072T3 (es) Anticuerpos optimizados que seleccionan como diana CD19
US8551485B2 (en) Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells
US20080254027A1 (en) Optimized CD5 antibodies and methods of using the same
US20080199471A1 (en) Optimized cd40 antibodies and methods of using the same
WO2011089211A1 (en) Anti-cd133 antibodies and methods of using the same
US20080206242A1 (en) Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
WO2008121160A2 (en) Optimized antibodies that target cd5
US20090162382A1 (en) Optimized ca9 antibodies and methods of using the same
WO2008091798A2 (en) Optimized ca9 antibodies and methods of using the same
HK1172910B (en) Anti-flt3 antibodies and methods of using the same
HK1131168B (en) Optimized antibodies that target cd19

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160524

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160526

R150 Certificate of patent or registration of utility model

Ref document number: 5944831

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250